PCI  - Contraindicated in pregnancy

LCI  - Contraindicated in lactation

Molecule Info

 

 | See TERMINOLOGY & ABBREVIATIONS |
Indication(s)

Hypertension

LOSARTAN and HYDROCHLOROTHIAZIDE tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.

Hypertensive Patients with Left Ventricular Hypertrophy

LOSARTAN and HYDROCHLOROTHIAZIDE tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients

Dosage & Administration

Hypertension

Dosing must be individualized. The usual starting dose of losartan is 50 mg once daily, with 25 mg recommended for patients with intravascular volume depletion (e.g., patients treated with diuretics) and patients with a history of hepatic impairment. Losartan can be administered once or twice daily at total daily doses of 25 to 100 mg. If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice-a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory response.

Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily and can be given at doses of 12.5 to 25 mg as Losartan Potassium and Hydrochlorothiazide tablets.

To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

The side effects (see WARNINGS) of losartan are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of losartan and hydrochlorothiazide will be associated with both sets of dose-independent side effects.

Replacement Therapy: The combination may be substituted for the titrated components.

Dose Titration by Clinical Effect: A patient whose blood pressure is not adequately controlled with losartan monotherapy or hydrochlorothiazide alone, may be switched to Losartan Potassium and Hydrochlorothiazide tablets 50 mg/12.5 mg (losartan 50 mg/hydrochlorothiazide 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dose may be increased to two tablets of Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg once daily or one tablet of Losartan Potassium and Hydrochlorothiazide 100 mg/25 mg (losartan 100 mg/hydrochlorothiazide 25 mg) once daily. A patient whose blood pressure is not adequately controlled with losartan 100 mg monotherapy (see above) may be switched to Losartan Potassium and Hydrochlorothiazide tablets 100 mg/12.5 mg once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dose may be increased to two tablets of Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg once daily or one tablet of LOSARTAN and HYDROCHLOROTHIAZIDE 100 mg/25 mg (losartan 100 mg/hydrochlorothiazide 25 mg) once daily.

A patient whose blood pressure is inadequately controlled by 25 mg once daily of hydrochlorothiazide, or is controlled but who experiences hypokalemia with this regimen, may be switched to Losartan Potassium and Hydrochlorothiazide tablets 50 mg/12.5 mg (losartan 50 mg/hydrochlorothiazide 12.5 mg) once daily, reducing the dose of hydrochlorothiazide without reducing the overall expected antihypertensive response. The clinical response to Losartan Potassium and Hydrochlorothiazide tablets 50 mg/12.5 mg should be subsequently evaluated, and if blood pressure remains uncontrolled after about 3 weeks of therapy, the dose may be increased to two tablets of Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg once daily or one tablet of Losartan Potassium and Hydrochlorothiazide 100 mg/25 mg (losartan 100 mg/ hydrochlorothiazide 25 mg) once daily.

The usual dose of LOSARTAN and HYDROCHLOROTHIAZIDE is one tablet of Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg once daily. More than two tablets of Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg once daily or more than one tablet of Losartan Potassium and Hydrochlorothiazide 100 mg/25 mg once daily is not recommended. The maximal antihypertensive effect is attained about 3 weeks after initiation of therapy.

Use in Patients with Renal Impairment: The usual regimens of therapy with Losartan Potassium and Hydrochlorothiazide tablets may be followed as long as the patient’s creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so Losartan Potassium and Hydrochlorothiazide tablet is not recommended.

Patients with Hepatic Impairment: Losartan Potassium and Hydrochlorothiazide tablet is not recommended for titration in patients with hepatic impairment because the appropriate 25 mg starting dose of losartan cannot be given.

Severe Hypertension
The starting dose of LOSARTAN and HYDROCHLOROTHIAZIDE tablets for initial treatment of severe hypertension is one tablet of Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg once daily. For patients who do not respond adequately to Losartan Potassium and Hydrochlorothiazide tablets 50 mg/12.5 mg after 2 to 4 weeks of therapy, the dosage may be increased to one tablet of Losartan Potassium and Hydrochlorothiazide 100 mg/25 mg once daily. The maximum dose is one tablet of Losartan Potassium and Hydrochlorothiazide 100 mg/25 mg once daily. Losartan Potassium and Hydrochlorothiazide tablets are not recommended as initial therapy in patients with hepatic impairment because the appropriate 25 mg starting dose of losartan cannot be given. It is also not recommended for use as initial therapy in patients with intravascular volume depletion (e.g., patients treated with diuretics).

Hypertensive Patients with Left Ventricular Hypertrophy
Treatment should be initiated with losartan potassium 50 mg once daily. Hydrochlorothiazide 12.5 mg should be added or Losartan Potassium and Hydrochlorothiazide tablets 50 mg/12.5 mg substituted if the blood pressure reduction is inadequate. If additional blood pressure reduction is needed, losartan potassium 100 mg and hydrochlorothiazide 12.5 mg or Losartan Potassium and Hydrochlorothiazide tablets 100 mg/12.5 mg may be substituted, followed by losartan potassium 100 mg and hydrochlorothiazide 25 mg or Losartan Potassium and Hydrochlorothiazide tablets 100 mg/25 mg. For further blood pressure reduction other antihypertensives should be added.

Losartan Potassium and Hydrochlorothiazide tablets may be administered with other antihypertensive agents.
Losartan Potassium and Hydrochlorothiazide tablets may be administered with or without food.

Overdosage

Losartan Potassium

Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m2 basis.

Limited data are available in regard to over dosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor its active metabolite can be removed by hemodialysis.

Hydrochlorothiazide

The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats. The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. 

Contraindications Pregnancy, lactation; intravascular volume depletion.
Special Precautions Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.
Adverse Drug Reaction(s) Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.
Potentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.
Drug Interactions

Losartan Potassium

No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite (See CLINICAL PHARMACOLOGY, Drug Interactions). In humans, two inhibitors of P450 3A4 have been studied. Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration. Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration. The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined. Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.

As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see PRECAUTIONS, Information for Patients, Potassium Supplements).

Lithium: As with other drugs which affect the excretion of sodium, lithium excretion may be reduced. Therefore, serum lithium levels should be monitored carefully if lithium salts are to be co-administered with angiotensin II receptor antagonists.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including losartan) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving losartan and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including losartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.

Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on Losartan Potassium and Hydrochlorothiazide tablets and other agents that affect the RAS.
Do not co-administer aliskiren with Losartan Potassium and Hydrochlorothiazide tablets in patients with diabetes. Avoid use of aliskiren with Losartan Potassium and Hydrochlorothiazide tablets in patients with renal impairment (GFR <60 ml/min).

Hydrochlorothiazide

When administered concurrently, the following drugs may interact with thiazide diuretics:

Alcohol, barbiturates, or narcotics â€“ potentiation of orthostatic hypotension may occur.

Antidiabetic drugs (oral agents and insulin) â€“ dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs â€“ additive effect or potentiation.

Cholestyramine and colestipol resins â€“ Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH, or glycyrrhizin (found in liquorice) â€“ intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., norepinephrine) â€“ possible decreased response to pressor amines but not sufficient to preclude their use.

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) â€“ possible increased responsiveness to the muscle relaxant.

Lithium â€“ should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with Losartan Potassium and Hydrochlorothiazide tablets.

Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) â€“ The administration of a non-steroidal anti-inflammatory agent, including a selective cyclooxygenase-2 inhibitor, can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losartan Potassium and Hydrochlorothiazide tablets and non-steroidal anti-inflammatory agents, including selective cyclooxygenase-2 inhibitors, are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

In patients receiving diuretic therapy, co-administration of NSAIDs with angiotensin receptor blockers, including losartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving hydrochlorothiazide, losartan, and NSAID therapy.

Food Interaction Avoid dong quai (if using for hypertension as it has estrogenic activity; ephedra, ginseng, yohimbe (may worsen hypertension), garlic (may have additive effects), St John's wort (may decrease levels).
Pregnancy Category (FDA)

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Category D: In 2nd & 3rd trimesters.There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Storage Protect from light and store at 15-30 °C.
Pharmacology Hydrochlorothiazide increases renal excretion of sodium and chloride and reduces cardiac load. Losartan is an angiotensin II receptor (type AT1) antagonist antihypertensive which acts by blocking the actions of angiotensin II of renin-angiotensin-aldosterone system. The drug and its active metabolite selectively block the vasoconstrictor and aldosterone secreting effects of angiotensin II. The two drugs exert additive effects in hypertension.
Onset: Hydrochlorothiazide: diuresis: approx 2 hr; losartan: 6 hr.
Duration: Hydrochlorothiazide: 6-12 hr.
Absorption: Hydrochlorothiazide: oral absorption: Approx 50-80%; time to peak: 1-2.5 hr; peak effect: 4-6 hr; bioavailability: 50-80%. Losartan: time to peak: 1 hr; losartan's active metabolite (E-3174): time to peak 3-4 hr (AUC is 4 times greater than that of losartan); bioavailability: 25-33%.
Distribution: Hydrochlorothiazide: 3.6-7.8 L/kg; protein binding: 68%. Losartan: volume of distribution: 34 L; plasma protein binding: high. Losartan's active metabolite (E-3174): volume of distribution:12 L.
Metabolism: Hydrochlorothiazide: Not metabolised. Losartan: Hepatic (14%) via CYP2CP and CYP3A4 to active metabolite, E-3174 (40 more times potent than losartan), extensive 1st-pass effect.
Excretion: Hydrochlorothiazide: half life elimination: 5.6-14.8 hr; excretion: via urine (as unchanged drug). Losartan: excretion via urine (4% as unchanged drug and 6% as active metabolite); plasma clearance: 600 ml/minute (active metabolite: 50 ml/min).
ATC Classification C09CA01 - losartan; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease. 
C03AA03 - hydrochlorothiazide; Belongs to the class of low-ceiling thiazide diuretics. Used to promote excretion of urine.

 

Brand/Product Info


Total Products : 43                                           
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
ANGILOCK PLUS 100/12.5 Square Pharmaceuticals Ltd. Losartan Potassium 100mg + Hydrochlorothiazide 12.5mg Tablet 3x10's: 330.90 MRP
ANGILOCK PLUS 100/25 Square Pharmaceuticals Ltd. Losartan Potassium 100mg + Hydrochlorothiazide 25mg Tablet 3x10's: 360.90 MRP
ANGILOCK PLUS 50/12.5 Square Pharmaceuticals Ltd. Losartan Potassium 50mg + Hydrochlorothiazide 12.5mg Tablet 5x10's: 401.50 MRP
ANIN 50 Plus Delta Pharma Limited Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 20's: 120.00 MRP
ANREB Plus 100 General Pharmaceuticals Ltd Losartan Potassium INN 100mg+ Hydrochlorothiazide 12.5mg Tablet 20's: 200.80 MRP
ANREB Plus 50 General Pharmaceuticals Ltd Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.60 MRP
ARATEN PIus-50 Unimed & Unihealth Manufacturers Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
CARDISAN Plus Beacon Pharmaceuticals Limited Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 195.00 MRP
CARDOPLUS 50 Eskayef Bangladesh Ltd Losartan Potassium 50mg +Hydrochlorothiazide 12.5mg Tablet 20's MRP: 120.00
HYPANIL Aexim Pharmaceutical Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 150.00 MRP
LARB 100 Plus Opsonin Pharma Limited Losartan Potassium INN 100mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 300.00 MRP
LARB 50 Plus Opsonin Pharma Limited Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
LK Plus Pacific Pharmaceuticals Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
LOK-50 Plus Globe Pharmaceuticals Ltd Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
LOPO Plus Biopharma Laboratories Ltd Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.60 MRP
LOPOS Plus Zenith Pharmaceuticals Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 500.00 MRP
LOSACARD-HZ Novo Healthcare and Pharma Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
LOSACOR PLUS Healthcare Pharmacuticals Ltd. Losartan potassium INN 50mg + Hydrochlorothiazide BP 12.5mg Tablet 30's MRP 240 Tk
LOSAN-D Orion Pharma Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.80 MRP
LOSARCAR-PLUS Medimet Pharmaceuticals Ltd Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 300.00 MRP
LOSARDIL-Plus 100/12.5 Drug International Ltd Losartan Potassium INN 100mg+ Hydrochlorothiazide 12.5mg Tablet 20's: 180.00 MRP
LOSARDIL-Plus 100/25 Drug International Ltd Losartan Potassium INN 100mg+ Hydrochlorothiazide 25mg Tablet 20's: 200.00 MRP
LOSARDIL-Plus 25 Drug International Ltd Losartan Potassium INN 25mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 250.00 MRP
LOSARDIL-Plus 50 Drug International Ltd Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 300.00 MRP
LOSART Plus The Acme Laboratories Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.60 MRP
LOSATAN HZ Popular Pharmaceuticals Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.59 MRP
LOSIUM PIus-50 IBN SINA Pharmaceutical Industry Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 195.00 IP
LOSPIL Plus The White Horse Pharma Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 300.00 MRP
LOTAS Plus Ambee Pharmaceuticals Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 150.60 MRP
OSARTAN-HZ Aristopharma Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
Osartil 100 Plus Incepta Pharmaceuticals Limited Losartan Potassium 100mg +Hydrochlorothiazide 25mg Tablet 10x3's:MRP 360 Tk
Osartil 50 Plus Incepta Pharmaceuticals Limited Losartan Potassium 50mg +Hydrochlorothiazide 12.5mg Tablet 10x5's:MRP 400 Tk
OSCARD Sharif Pharmaceuticals Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
OSTAN 100 Plus Renata Limited Losartan Potassium INN 100mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 300.00 MRP
OSTAN Plus Renata Limited Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.60 MRP
PARTEN Plus Jayson Pharmaceuticals Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.60 MRP
PERTILOS Navana Pharmaceuticals Limited Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.00 MRP
PROSAN HZ Beximco Pharmaceuticals Ltd Losartan potassium INN 50mg + Hydrochlorothiazide BP 12.5mg Tablet 30's: 240.00 MRP
PROSAN HZ 100/12.5 Beximco Pharmaceuticals Ltd Losartan potassium INN 100mg + Hydrochlorothiazide BP 12.5mg Tablet 30's: 270.00 MRP
PROSAN HZ 100/25 Beximco Pharmaceuticals Ltd Losartan potassium INN 100mg + Hydrochlorothiazide BP 25mg Tablet 30's: 300.00 MRP
REPACE H Sun Pharmaceutical (Bangladesh) Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 352.50 MRP
ROSATAN-H 25 ACI Ltd. Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 50's: 201.00 MRP
XELOTAN Plus Pharmasia Limited Losartan Potassium INN 50mg+ Hydrochlorothiazide 12.5mg Tablet 30's: 180.60 MRP
 | See Brand Manufacturer's Prescribing Information | | Back to top |